James K. Fong - 28 Feb 2022 Form 3 Insider Report for CTI BIOPHARMA CORP

Signature
/s/ Bruce J. Seeley, Attorney-in-fact for James K. Fong
Issuer symbol
N/A
Transactions as of
28 Feb 2022
Net transactions value
$0
Form type
3
Filing time
11 Mar 2022, 18:37:10 UTC
Next filing
26 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTIC Common Stock 3,565 28 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 360 $60.50 Direct F1
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 2,430 $35.70 Direct F2
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 3,700 $19.40 Direct F3
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 8,250 $4.48 Direct F4
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 10,000 $4.33 Direct F5
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 58,750 $3.19 Direct F6
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 23,340 $4.14 Direct F7
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 288,000 $0.9489 Direct F8
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 210,000 $1.00 Direct F9
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 115,000 $3.30 Direct F10
holding CTIC Stock Option (right to buy) 28 Feb 2022 Common Stock 210,000 $3.05 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents the right to purchase 360 shares of the Issuer's common stock and is fully vested.
F2 This option represents the right to purchase 2,430 shares of the Issuer's common stock and is fully vested.
F3 This option represents the right to purchase 3,700 shares of the Issuer's common stock and is fully vested.
F4 This option represents the right to purchase 8,250 shares of the Issuer's common stock and is fully vested.
F5 This option represents the right to purchase 10,000 shares of the Issuer's common stock and is fully vested.
F6 This option represents the right to purchase 58,750 shares of the Issuer's common stock and is fully vested.
F7 This option represents the right to purchase 23,340 shares of the Issuer's common stock and is fully vested.
F8 This option represents the right to purchase 288,000 shares of the Issuer's common stock and is fully vested.
F9 This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests in equal semi-annual installments beginning on September 11, 2020 through March 11, 2023, subject to the Reporting Person's continued service to the Issuer.
F10 This option represents the right to purchase 115,000 shares of the Issuer's common stock and vests in approximately equal semi-annual installments beginning on September 10, 2021 through March 10, 2024, subject to the Reporting Person's continued service to the Issuer.
F11 This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests 25% annually beginning on February 28, 2023, subject to the Reporting Person's continued service to the Issuer.

Remarks:

Senior Vice President and Chief Commercial Officer Exhibit 24 - Power of Attorney